Arterial endothelium-specific activin receptor-like kinase 1 expression suggests its role in arterialization and vascular remodeling

被引:221
作者
Seki, T [1 ]
Yun, JH [1 ]
Oh, SP [1 ]
机构
[1] Univ Florida, Coll Med, Dept Physiol & Funct Genom, Gainesville, FL 32610 USA
关键词
activin receptor-like kinase 1; hereditary hemorrhagic; telangiectasia; angiogenesis; vascular remodeling;
D O I
10.1161/01.RES.0000095246.40391.3B
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular disorder characterized by epistaxis, mucocutaneous telangiectases, and arteriovenous malformations (AVM). Two genes are linked to HHT: endoglin (ENG) in HHT1 and activin receptor-like kinase 1 (ACVRL1; ALK1) in HHT2. Although both genes are involved in the transforming growth factor beta signaling pathways, the pathogenetic mechanisms for HHT remain elusive. It was shown that mutations in the Alk1 gene in mice and zebrafish resulted in an embryonic lethal phenotype due to severe dilation of blood vessels. We created a novel null mutant mouse line for Alk1 (Alk1(lacZ)) by replacing its exons, including the one that encodes the transmembrane domain, with the beta-galactosidase gene. Using Alk1(lacZ) mice, we show that Alk1 is predominantly expressed in developing arterial endothelium. Alk1 expression is greatly diminished in adult arteries, but is induced in preexisting feeding arteries and newly forming arterial vessels during wound healing and tumor angiogenesis. We also show that hemodynamic changes, which require vascular remodeling, may regulate Alk1 expression. Our studies suggest the role of Alk1 signaling in arterialization and remodeling of arteries. Contrary to the current view of HHT as venous disease, our findings suggest that the arterioles rather than the venules are the primary vessels affected by the loss of an Alk1 allele, and that blood vessels with reduction in Alk1 expression may harbor defects in responding to demands for vascular remodeling.
引用
收藏
页码:682 / 689
页数:8
相关论文
共 36 条
[11]   TGF-β signal transduction [J].
Massagué, J .
ANNUAL REVIEW OF BIOCHEMISTRY, 1998, 67 :753-791
[12]   Alterations in TGF-β1 expression in lambs with increased pulmonary blood flow and pulmonary hypertension [J].
Mata-Greenwood, E ;
Meyrick, B ;
Steinhorn, RH ;
Fineman, JR ;
Black, SM .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2003, 285 (01) :L209-L221
[13]  
McDonald JE, 2000, AM J MED GENET, V93, P320, DOI 10.1002/1096-8628(20000814)93:4<320::AID-AJMG12>3.0.CO
[14]  
2-R
[15]   Activin receptor-like kinase 1 modulates transforming growth factor-β1 signaling in the regulation of angiogenesis [J].
Oh, SP ;
Seki, T ;
Goss, KA ;
Imamura, T ;
Yi, Y ;
Donahoe, PK ;
Li, L ;
Miyazono, K ;
ten Dijke, P ;
Kim, S ;
Li, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (06) :2626-2631
[16]   FLUID SHEAR-STRESS INDUCES ENDOTHELIAL TRANSFORMING GROWTH-FACTOR-BETA-1 TRANSCRIPTION AND PRODUCTION - MODULATION BY POTASSIUM CHANNEL BLOCKADE [J].
OHNO, M ;
COOKE, JP ;
DZAU, VJ ;
GIBBONS, GH .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (03) :1363-1369
[17]   Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-β in human umbilical vein endothelial cells [J].
Ota, T ;
Fujii, M ;
Sugizaki, T ;
Ishii, M ;
Miyazawa, K ;
Aburatani, H ;
Miyazono, K .
JOURNAL OF CELLULAR PHYSIOLOGY, 2002, 193 (03) :299-318
[18]   Type I receptor serine threonine kinase preferentially expressed in pulmonary blood vessels [J].
Panchenko, MP ;
Williams, MC ;
Brody, JS ;
Yu, Q .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 1996, 270 (04) :L547-L558
[19]   Expression analysis of four endoglin missense mutations suggests that haploinsufficiency is the predominant mechanism for hereditary hemorrhagic telangiectasia type 1 [J].
Pece-Barbara, N ;
Cymerman, U ;
Vera, S ;
Marchuk, DA ;
Letarte, M .
HUMAN MOLECULAR GENETICS, 1999, 8 (12) :2171-2181
[20]  
Roelen BAJ, 1997, DEV DYNAM, V209, P418, DOI 10.1002/(SICI)1097-0177(199708)209:4<418::AID-AJA9>3.3.CO